Advertisement

Topics

FDA Accepts Prometic’s BLA for its Rare Disease Drug Ryplazim

09:36 EDT 13 Oct 2017 | Speciality Pharma Journal

LAVAL, QC, Oct. 13, 2017 /PRNewswire/ – Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announced that the U.S Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for its plasminogen replacement therapy (RyplazimTM) having  granted a priority review status and set a Prescription Drug User Fee Act (PDUFA) action …

Original Article: FDA Accepts Prometic’s BLA for its Rare Disease Drug Ryplazim

NEXT ARTICLE

More From BioPortfolio on "FDA Accepts Prometic’s BLA for its Rare Disease Drug Ryplazim"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...